Advancing Psychosocial and Biobehavioral Stress Measurement to Understanding Aging

摘要 在新冠肺炎大流行的这个阶段，一个关键的问题已经成为了解个人可以 保持对疫苗的强大免疫力，哪些群体风险最高，哪些社会可塑性强， 行为因素、心理因素都能促进最佳维护。幸运的是，由于我们最初的R24 作为补充，我们启动了一项非凡的研究(Boost研究)，旨在解决这些问题 通过检查端粒长度、压力和行为因素作为预测因素，有94%的符合率。我们有 有机会检查同一队列中相同设计的第二次疫苗接种的反应，方法是添加 在加强接种疫苗后六个月收集数据。我们将是第一个能够研究 第一年接种疫苗后3个关键时间点的免疫反应轨迹 出去。我们可以解决我们最初的预测因素，白细胞端粒长度和慢性压力和年龄 相互作用(AIMS 1)作为新冠肺炎疫苗接种反应轨迹的预测因子(基于抗体 6周有应答，6个月和现在，新的加强免疫后6个月维持抗体 射门)。此外，我们现在可以测试这些因素如何预测突破性感染(目标2)。最后，这一点 补充剂允许我们收集细胞，使我们能够申请R01来检查T细胞对 疫苗接种(目标3)是免疫保护的关键部分，但由于体外成本的原因，研究很少。 细胞分析。现在新冠肺炎已经流行起来，这些问题对公众来说至关重要 未来几十年的健康。

ABSTRACT At this stage in the COVID-19 pandemic, a critical issue has become to understand how long individuals can maintain strong immunity from vaccinations, which groups are at highest risk, and what malleable social, behavioral, and psychological factors can promote optimal maintenance. Fortunately, due to our initial R24 supplement, we have launched a remarkable study (The BOOST Study) designed to address these questions by examining telomere length, stress, and behavioral factors as predictors with 94% adherence. We have the opportunity to examine response to a second vaccination with the same design in the same cohort, by adding data collection six months after the booster vaccination. We will be the first study to be able to examine the trajectory of immune responses at 3 critical post vaccination time points over the first year of vaccination roll out. We can address our original predictors, leukocyte telomere length and chronic stress and age interactions (Aims 1) as predictors of COVID-19 vaccination response trajectories (based on antibody response at 6 weeks, and maintenance of antibodies at 6 months and now, newly, 6 months after booster shot). Further, we can now test how these factors predict breakthrough infections (Aim 2). Lastly, this supplement allows us to collect cells enabling us to apply for an R01 to examine T cell responses to vaccination (Aim 3), a critical part of immune protection but rarely studied due to the costs of these in vitro cell assays. Now that COVID-19 has become endemic, these questions are of critical importance to public health for decades to come.